Chr del(11q)

Two cases with chromosomal aberrations in stromal cells were also identified. Expression of MYC protein was detected in 5 cases, of which 2 showed amplification of the MYC gene.

P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed

Our MR study provides strong evidence for a causal relationship between HLA DR on monocyte and MYCN-amplified NB, suggesting that elevated HLA DR expression may be a risk factor for this aggressive subtype. These findings could inform clinical decision-making regarding prognosis and treatment strategies for MYCN-amplified NB and may also identify potential therapeutic targets.

TP53 alterations are consistently associated with poor prognosis, whereas ATM mutations correlate with improved outcomes following rituximab-based chemotherapy...Functional analysis shows that p53 represses BCR signaling through PTPN6 activation. Collectively, these findings highlight distinct molecular and immune landscapes and reveal therapeutic vulnerabilities in high-risk TP53-perturbed MCL.

P1/2, N=19, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed

P2, N=42, Active, not recruiting, Jennifer Woyach | Trial primary completion date: Aug 2025 --> Dec 2025

P2, N=37, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Feb 2025 | Trial primary completion date: Jul 2025 --> Feb 2025

With up to 10 years of follow-up, we report results from the final analysis of RESONATE-2 (NCT01722487/NCT01724346), a phase 3 study of first-line ibrutinib versus chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). With the longest follow-up to date from a phase 3 study of any targeted CLL/SLL therapy, this landmark RESONATE-2 study defines median PFS and demonstrates continued OS benefit of first-line ibrutinib treatment for patients with CLL/SLL, including those with high-risk genomic features. Sustained efficacy and tolerability of ibrutinib reemphasize the favorable benefit-risk profile.

Similarly, among the subgroup of patients with Medicare coverage, the HR (95% CI) was 0.98 (0.63, 1.53), and median rwOS was not reached. In this real-world study using a large community healthcare dataset, there was no difference in rwOS between patients treated with 1L ibrutinib with and without high-risk cytogenetic features.

After adjusting for sex and CLL-International Prognostic Index (IPI), lymphadenopathy/splenomegaly was associated with a shorter TTFT (hazard ratio [HR] = 2.04, 95% confidence interval [CI]: 1.02-4.04, p = 0.042) but not OS (HR = 1.09, 95% CI: 0.62-1.92, p = 0.775). Lymphadenopathy/splenomegaly on imaging in individuals with high-count MBL is associated with a more unfavourable risk profile and shorter time to first CLL-directed therapy.

P2, N=234, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2025 --> Jul 2027

POLQ knockout impairs proliferation, enhances sensitivity to DNA damaging agents, and reduces tumor growth in vivo. These findings suggest that POLQ facilitates DNA damage tolerance in neuroblastoma and represents a viable therapeutic target.